Increasing unusual put option volume: SFM MQ QSR RVLV RCII ALL FTNT TNDM NTLA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'
August 4, 2022 11:06 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and {REMOVEPT} price target on Intellia Therapeutics (NASDAQ: NTLA)
The analyst comments "NTLA remains on track to present initial data from NTLA-2001 in ATTR-CM and NTLA-2002 in HAE in H2:22. The... More
RBC Capital on Intellia Therapeutics (NTLA) as Shares Like Over 10%: 'Stock Reaction Overdone'
August 4, 2022 10:17 AM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA announced today a new case of possibly drug-related liver enzyme elevation at 1 mg/kg and is backing off the dose going forward from... More
